RUTHERFORD, N.J., April 25, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at the Pioneers 2017 Conference presented by Joseph Gunnar & Co., LLC on Tuesday, May 2, 2017 at 9:00 AM Eastern Time, at the Mandarin Oriental Hotel in New York City.

Investors and interested parties may listen to the live webcast of this presentation by clicking here.

For additional information on the conference, including registration and company participation, please click here.

About Cancer Genetics, Inc.Cancer Genetics, Inc. is an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information. CGI is developing a global footprint with locations in the US, India and China. It has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:

Internet:  www.cancergenetics.com Twitter:  @Cancer_Genetics Facebook:  www.facebook.com/CancerGenetics

Forward-Looking Statements:This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the discovery, development and/or commercialization of potential therapies or products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

MEDIA CONTACT:Panna SharmaCancer Genetics, Inc.Tel: 201-528-9200Email: panna.sharma@cgix.comINVESTOR RELATIONS CONTACT:Richard MoyerCameron Associates535 Fifth Ave., New York, NY 10017Tel: 212-554-5466Email: richard@cameronassoc.com

Primary Logo